Corticobasal Syndrome (CBS) and Progressive Supranuclear Palsy (PSP) are both 4R tauopathies characterized by the accumulation of hyperphosphorylated tau protein, yet they exhibit distinct clinical phenotypes, neuroanatomical distributions, and genetic risk factors. Understanding their mechanistic differences is critical for accurate diagnosis and therapeutic development.
Both CBS and PSP belong to the spectrum of primary age-related tauopathies (PART) and share pathological features including 4-repeat (4R) tau inclusions. However, they differ in regional tau burden, clinical presentation, and underlying genetic architecture.
| Feature |
CBS |
PSP |
| Primary clinical phenotype |
Asymmetric cortical signs + parkinsonism |
Vertical gaze palsy + postural instability |
| Regional tau burden |
Frontoparietal cortex, basal ganglia |
Brainstem, globus pallidus, subthalamic nucleus |
| Typical onset age |
60-70 years |
60-70 years |
| Disease duration |
5-10 years |
5-10 years |
In CBS, tau pathology exhibits a cortical predominance with significant involvement of:
- Frontal and parietal cortex: Greatest tau burden, particularly in asymmetric distribution
- Basal ganglia: Caudate nucleus, putamen, and globus pallidus
- Substantia nigra: Moderate to severe neuronal loss
- Motor cortex: Involvement correlates with cortical signs
The cortical predominance explains the characteristic asymmetric apraxia, alien limb phenomena, and cortical sensory deficits observed in CBS patients.
In PSP, tau pathology shows a brainstem and subcortical predominance:
- Brainstem: Oculomotor nucleus, superior colliculus, pontine base
- Globus pallidus internus: Severe involvement
- Subthalamic nucleus: Pronounced neuronal loss
- Substantia nigra: Severe dopaminergic neuron loss
- Cerebellar nuclei: Variable involvement
The brainstem distribution explains vertical gaze palsy, early postural instability, and the classic Richardson syndrome phenotype.
Recent cryo-EM studies have revealed that CBS and PSP harbor distinct tau filament architectures, explaining their different clinical phenotypes despite both being 4R tauopathies.
Cryo-EM analysis of PSP tau filaments reveals characteristic double-helical filament conformations:
- PSP-specific fold: Distinct from CBD and AD tau folds
- Paired helical filament (PHF) variant: 4R tau with unique protofilament pairing
- Tight inter-protofilament contacts: Explains the dense filament bundles seen in PSP
CBS tau demonstrates distinct strain characteristics:
- CBS-specific filament architecture: Different from PSP and CBD
- Variable filament morphologies: Mixed PHF and straight filament populations
- Cortical predominance: Reflects the structural differences in seeding
Tau seed propagation studies reveal functional differences:
| Property |
CBS |
PSP |
| Seed efficiency |
Higher in cortical neurons |
Higher in brainstem neurons |
| Strain stability |
Less stable, more plastic |
More stable |
| Cell-to-cell transmission |
Cortical preference |
Brainstem preference |
| Template fidelity |
Variable |
High |
Tau strain biology has important therapeutic implications:
- Strain-specific therapies: Anti-tau antibodies may have differential efficacy
- Patient stratification: Tau strain profiling could guide treatment selection
- Biomarker development: Strain-specific CSF signatures may improve diagnosis
- Resistance mechanisms: Different strains may have varying drug sensitivity
flowchart TD
subgraph Tau_Strains
A["4R Tau"] --> B["CBS Strain"]
A --> C["PSP Strain"]
end
subgraph Structural_Differences
B --> D["Cortical Fold"]
C --> E["Brainstem Fold"]
end
subgraph Clinical_Phenotype
D --> F["Cortical Signs"]
E --> G["Brainstem Signs"]
end
Both conditions are associated with the MAPT H1 haplotype, but with different sub-haplotypes:
- PSP: Strongly associated with MAPT H1c subhaplotype
- CBS: Associated with broader H1 haplotype, including H1b and H1c
The MAPT gene encodes the tau protein, and specific haplotypes influence exon 10 splicing, affecting the 3R/4R tau ratio.
Genome-wide association studies (GWAS) have identified several PSP risk genes:
| Gene |
Function |
Risk Association |
| STX6 |
Syntaxin 6 - vesicle trafficking |
Strongest non-MAPT risk gene |
| EIF2AK3 |
ER stress response |
Significant association |
| MOBP |
Myelin-associated oligodendrocyte protein |
Moderate association |
| MAPT |
Microtubule-associated protein tau |
Primary genetic risk |
- STX6 Gene: Involved in intracellular vesicle trafficking. The rs242557 variant increases PSP risk by ~1.5x per allele.
- EIF2AK3 Gene: Encodes PERK, a key ER stress sensor. Variants may affect unfolded protein response.
CBS shows more complex genetics:
- Some cases are associated with CBD pathology (CBD)
- MAPT Gene mutations can cause both CBS and PSP phenotypes
- Less well-defined GWAS signal compared to PSP
- Asymmetric onset: Symptoms typically begin on one side
- Cortical signs:
- Apraxia (ideomotor, limb)
- Alien limb phenomenon
- Cortical sensory loss
- Aphasia (non-fluent variant)
- Extrapyramidal signs:
- Rigidity (asymmetric)
- Dystonia (focal, often hand)
- Myoclonus
- Cognitive impairment: Executive dysfunction, memory deficits
- Early postural instability: Falls within first year
- Vertical supranuclear gaze palsy: Downgaze > upgaze
- Axial rigidity: Neck extension (retrocollis)
- Pseudobulbar features: Dysarthria, dysphagia
- Cognitive impairment: Executive dysfunction, slowed processing
Both conditions have variant phenotypes:
PSP Variants:
- PSP-Parkinsonism (PSP-P)
- PSP-Pure Akinesia with Gait Freezing (PAGF)
- PSP-Corticobasal Syndrome (PSP-CBS)
- Frontal variant PSP
CBS Variants:
- CBS with Alzheimer pathology (CBS-AD)
- CBS with PSP pathology (CBS-PSP)
- Primary motor cortex (M1): Betz cell loss, tau in pyramidal neurons
- Premotor cortex: Tau in layer V neurons
- Posterior parietal cortex: Sensorimotor integration deficits
- Basal ganglia circuits: Disruption of direct/indirect pathways
- Superior colliculus: Tau in intermediate layer neurons
- Oculomotor nucleus: Vertical gaze control
- Substantia nigra pars compacta: Dopaminergic cell loss
- Globus pallidus internus: Output nucleus hyperactivity
- Subthalamic nucleus: Excitotoxic damage
Comparative neuroinflammation studies reveal distinct patterns between CBS and PSP:
| Feature |
CBS |
PSP |
| Regional distribution |
Cortical predominance |
Brainstem/basal ganglia |
| Activation state |
M1-like (pro-inflammatory) |
Mixed M1/M2 |
| TREM2 expression |
Elevated in cortex |
Elevated in brainstem |
| TSPO-PET signal |
Frontal > brainstem |
Brainstem > frontal |
- CBS: Higher IL-6, TNF-α in cortical regions
- PSP: Higher IL-1β in basal ganglia and brainstem
- CBS: More pronounced BBB dysfunction in cortical regions
- PSP: More prominent in brainstem regions
These differences may explain the differential efficacy of anti-inflammatory therapies in each condition.
Functional connectivity studies reveal distinct network signatures:
- Sensorimotor network: Asymmetric disruption
- Default mode network: Posterior cingulate involvement
- Frontoparietal network: Executive dysfunction correlates
- Subcortical networks: Prominent basal ganglia dysfunction
- Brainstem connectivity: Oculomotor network disruption
- Cerebellar networks: Gait and balance network involvement
Both conditions share potential therapeutic approaches:
- Tau reduction: Anti-tau antibodies, ASO therapies
- Tau phosphorylation modulation: Kinase inhibitors
- Tau aggregation inhibitors: Small molecule disruptors
- Neuroinflammation: Microglial modulation
- Mitochondrial support: Metabolic enhancement
For CBS:
- Cortical targeting may require blood-brain barrier (BBB) penetration strategies
- Asymmetric delivery approaches (focused ultrasound)
- Combined tau and amyloid targeting if CBS-AD
For PSP:
- Brainstem delivery advantages
- Earlier intervention due to rapid progression
- Targeting brainstem nuclei directly
flowchart TD
subgraph Shared_Risk
A["MAPT H1 Haplotype"] --> B["4R Tau Overexpression"]
C["Environmental Factors"] --> B
end
subgraph CBS_Pathology
B --> D["Cortical 4R Tau"]
D --> E["Tau in Pyramidal Neurons"]
E --> F["Synaptic Dysfunction"]
F --> G["Cortical Signs"]
E --> H["Basal Ganglia Involvement"]
H --> I["Extrapyramidal Signs"]
end
subgraph PSP_Pathology
B --> J["Brainstem 4R Tau"]
J --> K["Brainstem Neuron Loss"]
K --> L["Oculomotor Dysfunction"]
K --> M["Postural Instability"]
J --> N["Basal Ganglia Output"]
N --> O["Rigidity & Bradykinesia"]
end
CBS and PSP represent distinct clinical-pathological entities within the 4R tauopathy spectrum. While both involve MAPT dysfunction and 4R tau accumulation, critical differences in tau strain biology, regional pathology distribution, and neuroinflammatory patterns determine their divergent clinical phenotypes:
- CBS: Cortical predominance → asymmetric cortical signs + parkinsonism
- PSP: Brainstem predominance → vertical gaze palsy + postural instability
Recent cryo-EM studies have confirmed that CBS and PSP harbor distinct tau filament architectures (tau strains), explaining their different cellular tropism and clinical presentations despite both being 4R tauopathies. Additionally:
- Neuroinflammation: CBS shows cortical microglial predominance while PSP shows brainstem/basal ganglia patterns
- Network connectivity: CBS affects sensorimotor and frontoparietal networks; PSP affects subcortical and brainstem networks
The genetic architecture differs subtly, with PSP having well-defined GWAS signals (STX6, EIF2AK3) while CBS shows more heterogeneity. Understanding these differences is essential for:
- Accurate diagnosis (tau strain profiling may improve specificity)
- Prognostic counseling (different progression patterns)
- Clinical trial stratification (strain-specific therapeutic response)
- Personalized therapeutic approaches (targeting strain-specific mechanisms)